Prognostic and predictive impact of neutrophil‐to‐lymphocyte ratio and <scp>HLA‐I</scp> genotyping in advanced esophageal squamous cell carcinoma patients receiving immune checkpoint inhibitor monotherapy

Abstract

NLR and HLA-I genotyping could have predictive and prognostic value in patients with advanced ESCC receiving camrelizumab, and the combination of biomarkers may help to identify more patient benefit from immunotherapy.